

# Nadine Petitpain

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7288439/publications.pdf>

Version: 2024-02-01

21  
papers

488  
citations

840119

11  
h-index

676716

22  
g-index

25  
all docs

25  
docs citations

25  
times ranked

438  
citing authors

#	ARTICLE	IF	CITATIONS
1	Fatal anaphylaxis with neuromuscular blocking agents: a risk factor and management analysis. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2014, 69, 954-959.	2.7	99
2	Anaesthetic hypersensitivity reactions in France between 2011 and 2012: the 10th <scp>GERAP</scp> epidemiologic survey. <i>Acta Anaesthesiologica Scandinavica</i> , 2017, 61, 290-299.	0.7	97
3	Hypersensitivity reactions during anesthesia. Results from the ninth French survey (2005-2007). <i>Minerva Anestesiologica</i> , 2012, 78, 868-78.	0.6	81
4	Neuromuscular blocking agents induced anaphylaxis: Results and trends of a French pharmacovigilance survey from 2000 to 2012. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2018, 73, 2224-2233.	2.7	32
5	Nicorandil and ulcerations: a NAD/NADP and nicotinic acid-dependent side-effect?. <i>British Journal of Dermatology</i> , 2008, 158, 1150-1151.	1.4	30
6	Role of nicotinic acid and nicotinamide in nicorandil-induced ulcerations: from hypothesis to demonstration. <i>International Wound Journal</i> , 2015, 12, 527-530.	1.3	17
7	Hepatitis B reactivation and immune check point inhibitors. <i>Digestive and Liver Disease</i> , 2021, 53, 452-455.	0.4	15
8	Tumor necrosis factor inhibitors added to nonbiological immunosuppressants vs. nonbiological immunosuppressants alone: a different signal of cancer risk according to the condition. A disproportionality analysis in a nationwide pharmacovigilance database. <i>Fundamental and Clinical Pharmacology</i> , 2016, 30, 162-171.	1.0	14
9	Nicorandil and ulcerations: the Trojan horse?. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2012, 26, 925-926.	1.3	13
10	Nicorandil: from ulcer to fistula into adjacent organs. <i>International Wound Journal</i> , 2013, 10, 210-213.	1.3	12
11	A case of nicorandil-induced unilateral corneal ulceration. <i>International Wound Journal</i> , 2014, 11, 238-239.	1.3	12
12	Conjunctival and corneal ulcerations: keep a sharp eye on nicorandil. <i>British Journal of Ophthalmology</i> , 2012, 96, 463.2-464.	2.1	10
13	Detection of drug safety signals from clinical trials data: Role of SUSARs. <i>Pharmacological Research</i> , 2018, 131, 218-223.	3.1	10
14	Nicorandil-induced ulcerations: a 10-year observational study of all cases spontaneously reported to the French pharmacovigilance network. <i>International Wound Journal</i> , 2018, 15, 508-518.	1.3	10
15	Drug adulteration of sexual enhancement supplements: a worldwide insidious public health threat. <i>Fundamental and Clinical Pharmacology</i> , 2021, 35, 792-807.	1.0	10
16	Serious adverse drug events related to non-investigational drugs in academic clinical trials: another source of safety data for risk assessment?. <i>British Journal of Clinical Pharmacology</i> , 2016, 82, 1069-1075.	1.1	5
17	Is <scp>TNF</scp> inhibitor exposure a risk factor for amyotrophic lateral sclerosis?. <i>Fundamental and Clinical Pharmacology</i> , 2019, 33, 689-694.	1.0	5
18	Recurrent Dysphonia and Acitretin. <i>Journal of Voice</i> , 2006, 20, 642-643.	0.6	4

#	ARTICLE	IF	CITATIONS
19	Overview of clinical trials vigilance units in French institutional sponsors – A study from the REVISE working group. <i>Therapie</i> , 2021, 76, 743-750.	0.6	1
20	Severe headaches and 3rd or 6th nerve palsy associated with nicorandil: A hypothesis. <i>American Journal of Emergency Medicine</i> , 2018, 36, 1500-1501.	0.7	0
21	La pholcodine est-elle un facteur de risque pour l'allergie aux myorelaxants? <i>Revue Francaise D'allergologie</i> , 2018, 58, 155-156.	0.1	0